Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
- 1 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (1), 235-238
- https://doi.org/10.1038/s41375-020-0833-x
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validationsThe Lancet Haematology, 2019
- Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM studyHaematologica, 2018
- Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemiaBlood, 2014
- Applied Logistic RegressionPublished by Wiley ,2000